Gastro-Intestinal Symptoms and Autism Spectrum Disorder: A Potential Link [Response to Letter]

Eric D Shah

Section of Gastroenterology and
Hepatology, Dartmouth-Hitchcock
Health, Lebanon, NH, USA

Dear editor

Recognizing that our list of conditions associated with disorders of gut-brain interaction (DGBI) is not inclusive, we thank Drs. Mir, Sahito, and Ullah for considering associations between autism spectrum disorders (ASD) and DGBI.¹ On one hand, DGBI are incredibly common (comprising up to 40% of the general population).² Whether associations are truly causal or an epiphenomenon can be challenging to distinguish in research settings, and thus the implications of associations on direct clinical care in current practice must be approached with caution in an evidence-based manner.³ Yet it is important to recognize that this does not detract from the importance of appropriately managing each condition or from the need to seek new evidence in research settings. For ASD in particular, the conceptual overlap between pathophysiological constructs across both sets of conditions is significant and thus remains an active and rapidly growing area of ongoing research in recent years.

Our understanding of DGBIs more broadly now involves complex interrelated mechanisms within a broader gut-brain-microbiome axis.⁴ In ASD, differences in gut microbial diversity and content have been well described in recent years.^{5–7} Recent mouse models evaluating transplanted gut microbiota from humans with or without ASD suggests the importance of the gut microbiome and gut-brain in regulating symptoms consistent with DGBIs as well as ASD behaviors.⁸ Moving beyond these initial studies, learning how these changes manifest in human health (in a cause-and-effect manner) in prospective studies as well as understanding mechanisms that facilitate these potential effects remain needed—such that treatment for patients affected by ASD and DGBI can be individualized to meet the comprehensive needs of the patient by appropriate specialists for each condition.

Disclosure

Dr Eric D Shah received personal fees from GI Supply and Bausch Health, outside the submitted work. The author reports no conflicts of interest in this communication.

References

1. Moudgal R, Schultz AW, Shah ED. Systemic disease associations with disorders of gut–brain interaction and gastrointestinal transit: a review. *CEG*. 2021;14:249–257.

Correspondence: Eric D Shah
Center for Gastrointestinal Motility,
Esophageal, and Swallowing Disorders,
Section of Gastroenterology and
Hepatology, Dartmouth-Hitchcock
Health, One Medical Center Drive,
Lebanon, NH, 03756, USA
Tel +1 603 650-5261
Fax +1 603 727-7925
Email eric.d.shah@hitchcock.org

2. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. *Gastroenterology*. 2021;160(1):99-114.e3. doi:10.1053/j.gastro.2020.04.014
3. Shah E, Rezaie A, Riddle M, Pimentel M. Psychological disorders in gastrointestinal disease: epiphenomenon, cause or consequence? *Ann Gastroenterol*. 2014;27:224-230.
4. Margolis KG, Cryan JF, Mayer EA. The microbiota-gut-brain axis: from motility to mood. *Gastroenterology*. 2021;160:1486-1501. doi:10.1053/j.gastro.2020.10.066
5. Ihekweazu FD, Versalovic J. Development of the pediatric gut microbiome: impact on health and disease. *Am J Med Sci*. 2018;356:413-423. doi:10.1016/j.amjms.2018.08.005
6. Luna RA, Oezguen N, Balderas M, et al. Distinct microbiome-neuroimmune signatures correlate with functional abdominal pain in children with autism spectrum disorder. *Cell Mol Gastroenterol Hepatol*. 2017;3:218-230. doi:10.1016/j.jcmgh.2016.11.008
7. Wan Y, Zuo T, Xu Z, et al. Underdevelopment of the gut microbiota and bacteria species as non-invasive markers of prediction in children with autism spectrum disorder. *Gut*. 2021 [Epub]. doi:10.1136/gutjnl-2020-324015
8. Sharon G, Cruz NJ, Kang D-W, et al. Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. *Cell*. 2019;177:1600-1618.e17. doi:10.1016/j.cell.2019.05.004

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical and Experimental Gastroenterology 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical and Experimental Gastroenterology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical and Experimental Gastroenterology

Dovepress

Publish your work in this journal

Clinical and Experimental Gastroenterology is an international, peer-reviewed, open access, online journal publishing original research, reports, editorials, reviews and commentaries on all aspects of gastroenterology in the clinic and laboratory. This journal is indexed on American Chemical Society's Chemical Abstracts Service (CAS).

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-and-experimental-gastroenterology-journal>

<https://doi.org/10.2147/CEG.S337372>